In this study, a subset (3/50; 6%) of treatment naive NSCLC patients with ALK rearrangements also had concurrent EGFR activating mutations, suggesting that these mutations are not mutually exclusive and that the combination of both ALK and EGFR inhibitors may be an effective strategy for certain subgroups of NSCLC patients [109]. This evidence concerns the gene ALK and non-small cell lung carcinoma.